BACKGROUND: The International Neuroblastoma Pathology Committee, which is comprised of six member pathologists, was convened with the objective of proposing a prognostically significant and biologically relevant classification based on morphologic features of neuroblastic tumors (NTs) (i.e., neuroblastoma, ganglioneuroblastoma, and ganglioneuroma). METHODS: A total of 227 cases were reviewed. Consensus diagnoses from morphologic features (criteria described separately) based on five of six or six of six agreements by the reviewer pathologists were used for prognostic analysis. Prognostic effects of morphology, both individual and in combination, taken in conjunction with age (Shimada classification, histologic grade, and risk group), were analyzed. RESULTS: Approximately 99% of cases (224 of 227) had consensus diagnoses for categorization: neuroblastoma (Schwannian stroma-poor), 190 cases; ganglioneuroblastoma, intermixed (Schwannian stroma-rich), 5 cases; ganglioneuroma (Schwannian stroma-dominant) maturing, 1 case; ganglioneuroblastoma, nodular (composite Schwannian stroma-rich/stroma-dominant and stroma-poor), 19 cases; and NT-unclassifiable, 9 cases. For the NTs, subtype (93% consensus: undifferentiated, 6 cases; poorly differentiated, 155 cases; and differentiated, 15 cases), mitosis-karyorrhexis index (90% consensus: low, 94 cases; intermediate, 40 cases; and high, 37 cases), mitotic rate (75% consensus: low, 89 cases; high, 50 cases; and not determined, 4 cases), and calcification (100% consensus: yes, 110 cases and no, 80 cases) were recorded. Statistical analysis demonstrated that the Shimada classification system (90% consensus; 3-year event free survival: 85% for the group with favorable histology and 41% for the group with unfavorable histology; P = 0.31 x 10(-9)) had a significantly stronger prognostic effect than individual features and other combinations. CONCLUSIONS: The International Neuroblastoma Pathology Classification, a system based on a framework of the Shimada classification with minor modifications, is proposed for international use in assessing NTs.
BACKGROUND: The International Neuroblastoma Pathology Committee, which is comprised of six member pathologists, was convened with the objective of proposing a prognostically significant and biologically relevant classification based on morphologic features of neuroblastic tumors (NTs) (i.e., neuroblastoma, ganglioneuroblastoma, and ganglioneuroma). METHODS: A total of 227 cases were reviewed. Consensus diagnoses from morphologic features (criteria described separately) based on five of six or six of six agreements by the reviewer pathologists were used for prognostic analysis. Prognostic effects of morphology, both individual and in combination, taken in conjunction with age (Shimada classification, histologic grade, and risk group), were analyzed. RESULTS: Approximately 99% of cases (224 of 227) had consensus diagnoses for categorization: neuroblastoma (Schwannian stroma-poor), 190 cases; ganglioneuroblastoma, intermixed (Schwannian stroma-rich), 5 cases; ganglioneuroma (Schwannian stroma-dominant) maturing, 1 case; ganglioneuroblastoma, nodular (composite Schwannian stroma-rich/stroma-dominant and stroma-poor), 19 cases; and NT-unclassifiable, 9 cases. For the NTs, subtype (93% consensus: undifferentiated, 6 cases; poorly differentiated, 155 cases; and differentiated, 15 cases), mitosis-karyorrhexis index (90% consensus: low, 94 cases; intermediate, 40 cases; and high, 37 cases), mitotic rate (75% consensus: low, 89 cases; high, 50 cases; and not determined, 4 cases), and calcification (100% consensus: yes, 110 cases and no, 80 cases) were recorded. Statistical analysis demonstrated that the Shimada classification system (90% consensus; 3-year event free survival: 85% for the group with favorable histology and 41% for the group with unfavorable histology; P = 0.31 x 10(-9)) had a significantly stronger prognostic effect than individual features and other combinations. CONCLUSIONS: The International Neuroblastoma Pathology Classification, a system based on a framework of the Shimada classification with minor modifications, is proposed for international use in assessing NTs.
Authors: R Amitay; D Nass; D Meitar; I Goldberg; B Davidson; L Trakhtenbrot; F Brok-Simoni; A Ben-Ze'ev; G Rechavi; Y Kaufmann Journal: Am J Pathol Date: 2001-07 Impact factor: 4.307
Authors: Rie Suganuma; Larry L Wang; Hideki Sano; Arlene Naranjo; Wendy B London; Robert C Seeger; Michael D Hogarty; Julie M Gastier-Foster; A Thomas Look; Julie R Park; John M Maris; Susan L Cohn; Gabriele Amann; Klaus Beiske; Catherine J Cullinane; Emanuele S G d'Amore; Claudio Gambini; Jason A Jarzembowski; Vijay V Joshi; Samuel Navarro; Michel Peuchmaur; Hiroyuki Shimada Journal: Pediatr Blood Cancer Date: 2012-06-28 Impact factor: 3.167
Authors: Yania Yáñez; David Hervás; Elena Grau; Silvestre Oltra; Gema Pérez; Sarai Palanca; Mar Bermúdez; Catalina Márquez; Adela Cañete; Victoria Castel Journal: J Cancer Res Clin Oncol Date: 2015-10-24 Impact factor: 4.553
Authors: Navin Pinto; Jodi R Mayfield; Gordana Raca; Mark A Applebaum; Alexandre Chlenski; Madina Sukhanova; Rochelle Bagatell; Meredith S Irwin; Anthony Little; Jawhar Rawwas; Yasmin Gosiengfiao; Olivier Delattre; Isabelle Janoueix-Lerosey; Eve Lapouble; Gudrun Schleiermacher; Susan L Cohn Journal: Pediatr Blood Cancer Date: 2016-02-10 Impact factor: 3.167
Authors: Shuqing Liu; Yufeng Tian; Alexandre Chlenski; Qiwei Yang; Peter Zage; Helen R Salwen; Susan E Crawford; Susan L Cohn Journal: Am J Pathol Date: 2005-03 Impact factor: 4.307
Authors: Henning C Fiegel; Jussuf T Kaifi; Robin Wachowiak; Alexander Quaas; Kuniaki Aridome; Keiko Ichihara-Tanaka; Takashi Muramatsu; Roman Metzger; Jakob R Izbicki; Rudolf Erttmann; Dietrich Kluth; Holger Till Journal: Pediatr Surg Int Date: 2008-12 Impact factor: 1.827
Authors: Stefano Avanzini; Isabella Buffoni; Anna Rita Gigliotti; Stefano Parodi; Irene Paraboschi; Alessandro Inserra; Patrizia Dall'Igna; Anna Maria Fagnani; Giuseppe Martucciello; Mario Lima; Umberto Caccioppoli; Alberto Garaventa; Massimo Conte; Claudio Granata; Angela Rita Sementa; Elisa Tirtei; Giovanni Erminio; Bruno De Bernardi Journal: Pediatr Surg Int Date: 2020-10-29 Impact factor: 1.827